Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.
about
Molecularly targeted drugs for metastatic colorectal cancerAngiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy ModelsPreclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivityEvidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer.Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.Caffeic acid derivatives, analogs and applications: a patent review (2009-2013).Targeted therapies in gastric cancer treatment: where we are and where we are going.γ-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules.New agents on the horizon in gastric cancer.Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory.Tumor angiogenesis revisited: Regulators and clinical implications.
P2860
Q26828735-0CB4A62F-A905-4255-8E6D-547E13E386DDQ27002538-6EAEC654-9822-4C75-B625-1C3901FB4DBEQ27345024-4C6D1309-5A0B-40BC-87C0-647A4E98D265Q36801184-C9AF11C8-E596-4765-9E41-C41E42D1D86BQ37408810-5489DCFC-7B50-485E-8239-FCB6BDD116E5Q38166273-7F2B8E19-4979-4268-9A50-9571DD263749Q38166329-E99CE5E0-8FF4-43FF-94F7-D05F9D265203Q38256950-3D11EACE-F4CD-48D7-84A7-051746F0D07FQ38731943-61A97DE2-6B69-4E08-B862-98050095FD70Q38749027-AAFAE188-333C-43DD-9DCD-A26C45E3C01BQ38759129-5E8BD914-8C15-4765-B7E9-84E4D72FA6FEQ38827897-F26C5CB3-1042-411C-B55C-F2F86D2C7945Q39393740-EAA61B27-7105-430B-BC40-E8C546ADDD65
P2860
Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Regorafenib for gastrointestin ...... novel multi-target inhibitor.
@ast
Regorafenib for gastrointestin ...... novel multi-target inhibitor.
@en
type
label
Regorafenib for gastrointestin ...... novel multi-target inhibitor.
@ast
Regorafenib for gastrointestin ...... novel multi-target inhibitor.
@en
prefLabel
Regorafenib for gastrointestin ...... novel multi-target inhibitor.
@ast
Regorafenib for gastrointestin ...... novel multi-target inhibitor.
@en
P2093
P2860
P1433
P1476
Regorafenib for gastrointestin ...... novel multi-target inhibitor.
@en
P2093
Francesco Giuliani
Giuseppe Aprile
Marianna Macerelli
P2860
P2888
P304
P356
10.1007/S40259-013-0014-9
P577
2013-06-01T00:00:00Z